The short answer: biotech investors in 2026 rely on a mix of sources, because no single newsletter covers catalysts, deal flow, commercial data, and analysis equally well. STAT leads on market moving investigative reporting, Endpoints News leads on breaking deals and clinical news, Evaluate Vantage leads on commercial forecasting, Timmerman Report leads on long form perspective, and BioMed Nexus leads on tracking catalysts, funding, and deals in a single daily brief. Most serious investors read several.
Here is how the field compares for an investing audience.
Comparison chart: newsletters for investors
| Newsletter | Strength for investors | Format | Price |
|---|---|---|---|
| STAT (The Readout) | Market moving investigative reporting | Daily and weekly | Freemium, best in STAT+ |
| Endpoints News | Breaking deals and clinical news | Multiple emails | Freemium |
| Evaluate Vantage | Commercial forecasts and market data | Regular | Paid |
| Timmerman Report | Long form analysis and industry voices | Weekly | Paid |
| BioPharma Dive | Concise daily news | Daily | Free |
| BioMed Nexus | Catalysts, funding, and deal tracking | Daily brief | Free |
What investors actually need from a newsletter
Catalysts and timing. Clinical readouts, PDUFA dates, and regulatory decisions move stocks, and knowing the calendar matters. BioMed Nexus and Endpoints both track these closely, and BioMed Nexus frames them as dated events you can plan around.
Deal flow. Mergers, acquisitions, and licensing deals reprice whole subsectors. Endpoints and STAT break these, and BioMed Nexus reads what each deal means for the companies around it.
Commercial data. For the numbers behind a thesis, Evaluate Vantage is the reference for forecasts and market sizing, though it is a paid product built for professionals.
Independent analysis. Timmerman Report and STAT’s columnists provide the kind of skeptical, experienced perspective that helps separate a real result from a good press release.
Build an investor stack
A typical investor stack pairs one breaking news source, one data source, and one that tracks catalysts and deals. For example, STAT or Endpoints for news, Evaluate for data, and BioMed Nexus for a free daily read on catalysts and deal activity. The combination covers what happened, what it is worth, and what is coming next.
Frequently asked questions
What newsletter do biotech investors read?
Most read several. STAT and Endpoints News for breaking news, Evaluate Vantage for commercial data, Timmerman Report for analysis, and BioMed Nexus for a free daily read on catalysts, funding, and deals.
Is there a free newsletter for biotech investing?
Yes. BioPharma Dive and BioMed Nexus are both free and useful for investors, with BioMed Nexus focusing on the catalysts, funding rounds, and deals that tend to move the sector.
How do I track biotech catalysts and PDUFA dates?
Several newsletters cover the catalyst calendar. BioMed Nexus tracks regulatory decisions and clinical readouts as dated events, and specialist trackers and paid data services offer more detailed calendars.
What is the best way to read a clinical trial result as an investor?
Focus on whether the primary endpoint hit, the effect size in absolute terms, and the confidence interval, rather than the framing of the press release. Newsletters that decode readouts rather than just report them are the most useful for this.
Read the BioMed Nexus daily brief
BioMed Nexus is a free daily brief read by more than 65,000 biotech and pharma professionals, tracking the catalysts, funding rounds, and deals that reprice the sector.
